Brevan Howard Capital Management LP Makes New Investment in Insulet Co. (NASDAQ:PODD)

Brevan Howard Capital Management LP bought a new position in shares of Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,168 shares of the medical instruments supplier’s stock, valued at approximately $305,000.

Several other institutional investors have also modified their holdings of PODD. Captrust Financial Advisors boosted its stake in shares of Insulet by 24.1% during the 4th quarter. Captrust Financial Advisors now owns 2,185 shares of the medical instruments supplier’s stock valued at $570,000 after buying an additional 425 shares during the last quarter. Bayesian Capital Management LP bought a new position in Insulet during the 4th quarter valued at $2,071,000. BLI Banque de Luxembourg Investments acquired a new position in Insulet during the 4th quarter worth $13,749,000. Wahed Invest LLC raised its stake in shares of Insulet by 4.1% in the 4th quarter. Wahed Invest LLC now owns 1,766 shares of the medical instruments supplier’s stock valued at $461,000 after purchasing an additional 70 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new position in shares of Insulet during the fourth quarter worth about $42,000.

Insider Buying and Selling at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.47% of the stock is owned by corporate insiders.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $310.42 on Friday. The stock has a market cap of $21.84 billion, a price-to-earnings ratio of 53.61, a PEG ratio of 3.62 and a beta of 1.26. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $312.16. The stock’s 50 day moving average price is $257.45 and its 200 day moving average price is $263.70.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. The company’s revenue was up 28.8% on a year-over-year basis. Equities research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on PODD shares. Wolfe Research lowered Insulet from an “outperform” rating to a “peer perform” rating in a report on Tuesday, April 29th. Raymond James restated an “outperform” rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Royal Bank of Canada started coverage on shares of Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. StockNews.com downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, Oppenheimer boosted their price objective on shares of Insulet from $312.00 to $324.00 and gave the company an “outperform” rating in a research report on Friday. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $303.81.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.